Livzon Pharmaceutical Group
Organization
Trials
A Prospective Trial of SFI Plus PD-1 Inhibitors and PBC in Resectable NSCLC (SFI-NSCLC)
Collaborator, Phase 4, Not yet recruiting, 30 people, Sep 28, 2026
Phase 2, Recruiting, 320 people, May 9, 2025
Phase 3, Status unknown, 918 people, Nov 1, 2023
Phase 3, Completed, 449 people, May 3, 2023
Early phase 1, Status unknown, 40 people, Oct 17, 2022
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
Phase 3, Completed, 540 people, Dec 5, 2017
IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
Phase 2, Completed, 180 people, Dec 5, 2017
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Phase 3, Completed, 550 people, Aug 9, 2016
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Phase 2, Status unknown, 330 people, Apr 21, 2010
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)
Phase 2, Completed, 235 people, Aug 6, 2009
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)
Phase 3, Completed, 496 people, Aug 6, 2009
Sources: clinicaltrials.gov